Development and License Agreements - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended
	Sep. 30, 2022	Sep. 30, 2020	Mar. 31, 2025	Dec. 31, 2024	Sep. 30, 2024	Sep. 30, 2023
BARDA Agreement
Licenses Agreements [Line Items]
Additional committed fund receivable						$ 3,500,000
Committed fund receivable			$ 185,500,000
Reduction in committed fund receivable			8,800,000
Committed fund receivable			270,200,000
Receivable of billed and unbilled amounts			2,700,000	$ 2,400,000
BARDA Agreement | Cerus Corporation | Maximum
Licenses Agreements [Line Items]
Co-investment by the company			1,400,000
2024 BARDA Agreement
Licenses Agreements [Line Items]
Committed fund receivable					$ 32,100,000
Committed fund receivable			188,400,000
2024 BARDA Agreement | Accounts Receivable, Net
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			300	100
2024 BARDA Agreement | Cerus Corporation | Maximum
Licenses Agreements [Line Items]
Co-investment by the company			60,100,000
FDA Agreement
Licenses Agreements [Line Items]
Contract agreement term		5 years
Total potential contract value		$ 11,100,000
FDA Agreement | Accounts Receivable, Net
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			700,000	500,000
DoD and IBAS Program Agreement | Accounts Receivable, Net
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			0	1,000,000
DoD and IBAS Program Agreement | Deferred Revenue
Licenses Agreements [Line Items]
Receivable of billed and unbilled amounts			$ 100,000	$ 500,000
DoD and IBAS Program Agreement | Maximum
Licenses Agreements [Line Items]
Total contract value	$ 17,800,000
DoD and IBAS Program Agreement | Minimum
Licenses Agreements [Line Items]
Total contract value	$ 9,100,000